Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Cancer Therapies02:49

Cancer Therapies

7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

5.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radiation therapy of the primary tumour and/or metastases of digestive metastatic cancers.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2023
Same author

Esophageal cancer - French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFP, RENAPE, SNFCP, AFEF, SFR).

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2023
Same author

[News in gastrointestinal radiotherapy: The esophageal cancer].

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2022
Same author

Radiotherapy for cancers of the oesophagus, cardia and stomach.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2021
Same author

Radiation therapy of cutaneous cancers.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2021
Same author

Tumour and normal tissue radiosensitivity.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2021
Same journal

White paper on radiotherapy in France: Ten objectives to strengthen one of the major modalities of cancer treatment.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2026
Same journal

Contemporary survival outcomes of patients with isolated nodal recurrences of breast cancer: A population-based study.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2026
Same journal

Factors affecting the stability of deep inspiration breath-holding in radiotherapy for left-sided breast cancers.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2026
Same journal

Incidence and outcomes of radiation-induced sarcomas following radiotherapy for low-grade non-Hodgkin lymphomas: A population-based study.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2026
Same journal

Radiotherapy as a curative strategy for primary pleural indolent lymphomas: Analytical guidelines based on literature and an illustrative population-based case series.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2026
Same journal

Cone-beam computed tomography-based radiomics for tumour regression assessment during radiotherapy of non-small-cell lung cancer.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2026
See all related articles

Related Experiment Video

Updated: Aug 31, 2025

Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine
05:39

Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine

Published on: April 5, 2024

932

Radiotherapy and CDK inhibitors: Opportunities and risks.

T Brion1, L Quéro2

  • 1Institut Gustave-Roussy, département d'oncologie radiothérapie, 114, rue Edouard-Vaillant, Villejuif, France.

Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique
|August 21, 2022
PubMed
Summary
This summary is machine-generated.

Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with radiotherapy show potential synergistic effects but may increase toxicity. Discontinuing CDK4/6 inhibitors before irradiation is advisable pending further clinical trials.

Keywords:
Cyclin-dependent kinase 4Cyclin-dependent kinase 6Kinase-4 cycline-dépendanteKinase-6 cycline-dépendanteRadiosensibilisationRadiosensitizationRadiotherapyRadiothérapieToxicityToxicité

More Related Videos

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.6K
Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
08:32

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

419

Related Experiment Videos

Last Updated: Aug 31, 2025

Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine
05:39

Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine

Published on: April 5, 2024

932
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.6K
Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
08:32

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

419

Area of Science:

  • Oncology
  • Radiotherapy
  • Pharmacology

Background:

  • CDK4/6 inhibitors are standard treatment for metastatic HR+/HER2- breast cancer.
  • Combining CDK4/6 inhibitors with radiotherapy is being investigated for enhanced anti-cancer effects.
  • Pre-clinical data suggest potential synergistic outcomes in various cancer types.

Purpose of the Study:

  • To review the benefits and risks of combining CDK4/6 inhibitors with radiotherapy.
  • To synthesize current evidence on the safety and efficacy of this combined treatment modality.

Main Methods:

  • Literature review of pre-clinical and clinical studies.
  • Analysis of reported synergistic effects and toxicities.
  • Identification of ongoing prospective clinical trials.

Main Results:

  • Pre-clinical studies indicate a potential synergistic effect between CDK4/6 inhibitors and radiotherapy.
  • Retrospective clinical studies suggest increased acute toxicity, particularly with digestive or pulmonary irradiation.
  • Discontinuation of CDK4/6 inhibitors prior to radiotherapy is suggested based on toxicity findings.

Conclusions:

  • The combination of CDK4/6 inhibitors and radiotherapy presents a complex risk-benefit profile.
  • Careful patient selection and treatment sequencing may be necessary to mitigate toxicity.
  • Prospective clinical trials are crucial to establish the definitive safety and efficacy of this combination therapy.